Skip to main content
. 2022 Apr 13;23(6):170. doi: 10.3892/ol.2022.13290

Figure 4.

Figure 4.

Tepotinib restrains activation of MET and PI3K/AKT signaling pathways in melanoma cells. The expression levels of p-MET, MET, p-PI3K, PI3K, p-AKT and AKT in WM451 cells treated with or without 10 ng/ml tepotinib were determined using western blot analysis. *P<0.05, **P<0.01 and ***P<0.001 vs. control (DMSO) group. MET, MET proto-oncogene, receptor tyrosine kinase; p-, phosphorylated.